74 related articles for article (PubMed ID: 28761967)
1. Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer.
Kenmotsu H; Ohde Y; Wakuda K; Nakashima K; Omori S; Ono A; Naito T; Murakami H; Kojima H; Takahashi S; Isaka M; Endo M; Takahashi T
Cancer Chemother Pharmacol; 2017 Sep; 80(3):609-614. PubMed ID: 28761967
[TBL] [Abstract][Full Text] [Related]
2. Oral fluorouracil vs vinorelbine plus cisplatin as adjuvant chemotherapy for stage II-IIIA non-small cell lung cancer: Propensity score-matched and instrumental variable analyses.
Urushiyama H; Jo T; Yasunaga H; Michihata N; Matsui H; Hasegawa W; Takeshima H; Sakamoto Y; Hiraishi Y; Mitani A; Fushimi K; Nagase T; Yamauchi Y
Cancer Med; 2018 Oct; 7(10):4863-4869. PubMed ID: 30151905
[TBL] [Abstract][Full Text] [Related]
3. Phase II Trial of Adjuvant Atezolizumab Therapy in Elderly Patients with Completely Resected Stage II/III Non-Small Cell Lung Cancer: RELIANCE Trial.
Matsubara T; Yamaguchi M; Shimokawa M; Okamoto I
Clin Lung Cancer; 2024 May; 25(3):280-283. PubMed ID: 38368174
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of adjuvant therapy for cisplatin-unfit patients with non-small-cell lung cancer: A multicenter analysis.
Noritake O; Nakamura S; Kinoshita F; Aokage K; Asao T; Matsuura Y; Chen-Yoshikawa TF
Lung Cancer; 2024 Feb; 188():107470. PubMed ID: 38237212
[TBL] [Abstract][Full Text] [Related]
5. Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer.
Ma X; Rousseau V; Sun H; Lantuejoul S; Filipits M; Pirker R; Popper H; Mendiboure J; Vataire AL; Le Chevalier T; Soria JC; Brambilla E; Dunant A; Hainaut P;
Mol Oncol; 2014 May; 8(3):555-64. PubMed ID: 24495481
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy after complete resection of non-small cell lung cancer.
Laack E; Bokemeyer C; Hossfeld DK
Dtsch Arztebl Int; 2008 Apr; 105(14):249-54. PubMed ID: 19629205
[TBL] [Abstract][Full Text] [Related]
7. Impact of
Akazawa Y; Higashiyama M; Nishino K; Uchida J; Kumagai T; Inoue T; Fujiwara A; Tokunaga T; Okami J; Imamura F; Kodama K; Kobayashi H
Mol Clin Oncol; 2017 Sep; 7(3):327-335. PubMed ID: 28811897
[TBL] [Abstract][Full Text] [Related]
8. A Rare Case of Complete-Immunotherapy-Responsive Metastatic Non-Small Cell Lung Cancer with Long Lasting Progression-Free Survival: A Case Report.
De Intinis C; Izzo P; Codacci-Pisanelli M; Izzo L; Messineo D; Sibio S; Campagnol M; Lai S; Molle M; Izzo S
Curr Oncol; 2024 Jan; 31(2):723-732. PubMed ID: 38392047
[TBL] [Abstract][Full Text] [Related]
9. Clustered circulating tumor cells as a predictor of adjuvant-chemotherapy efficacy in lung cancer.
Sawabata N; Hamaji M; Yoshikawa D; Miyata R; Kawaguchi T
Ann Thorac Surg; 2024 May; ():. PubMed ID: 38789007
[TBL] [Abstract][Full Text] [Related]
10. Study-design of adjuvant chemotherapy for lung cancer: A cart before the horse.
Takahashi T
Ann Thorac Surg; 2024 Apr; ():. PubMed ID: 38621654
[No Abstract] [Full Text] [Related]
11. LACES and bootstraps: the hunt for prognostic and predictive markers for adjuvant therapy in NSCLC.
Lee RC; Thapa B; John T
Transl Lung Cancer Res; 2018 Sep; 7(Suppl 3):S239-S242. PubMed ID: 30393612
[No Abstract] [Full Text] [Related]
12. A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients.
Imai H; Sugiyama T; Tamura T; Minemura H; Kaira K; Kanazawa K; Yokouchi H; Kasai T; Kaburagi T; Minato K;
Cancer Chemother Pharmacol; 2017 Sep; 80(3):615-622. PubMed ID: 28761968
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of small advanced gastric cancer (≤ 40 mm) in elderly patients: A retrospective cohort study.
Ueda Y; Fujishima H; Hirashita T; Shiroshita H; Etoh T; Inomata M; Shiraishi N
Int J Surg; 2017 Sep; 45():131-137. PubMed ID: 28782661
[TBL] [Abstract][Full Text] [Related]
14. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial.
Ferry D; Billingham L; Jarrett H; Dunlop D; Woll PJ; Nicolson M; Shah R; Thompson J; Spicer J; Muthukumar D; Skailes G; Leonard P; Chetiyawardana AD; Wells P; Lewanski C; Crosse B; Hill M; Gaunt P; O'Byrne K
Eur J Cancer; 2017 Sep; 83():302-312. PubMed ID: 28780466
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non-Small Cell Lung Cancer.
Furuta H; Yoshida T; Shimizu J; Tomita N; Yatabe Y; Hida T
J Thorac Oncol; 2017 Nov; 12(11):1733-1736. PubMed ID: 28774862
[No Abstract] [Full Text] [Related]
16. Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer.
Ciuleanu TE; Ahmed S; Kim JH; Mezger J; Park K; Thomas M; Chen J; Poondru S; VanTornout JM; Whitcomb D; Blackhall F
Br J Cancer; 2017 Sep; 117(6):757-766. PubMed ID: 28772281
[TBL] [Abstract][Full Text] [Related]
17. Prevention of vasculitis and vascular pain by side route administration of vinorelbine: A case report.
Ishii S; Ichimura T; Ichikura D
Clin Case Rep; 2023 May; 11(5):e7258. PubMed ID: 37151952
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy for completely resected IIA-IIIA non-small cell lung cancer: compliance to guidelines, safety and efficacy in real-life practice.
Désage AL; Tissot C; Bayle-Bleuez S; Muron T; Deygas N; Grangeon-Vincent V; Monange B; Torche F; Vercherin P; Kaczmarek D; Tiffet O; Forest F; Vergnon JM; Bouleftour W; Fournel P
Transl Lung Cancer Res; 2022 Dec; 11(12):2418-2437. PubMed ID: 36636405
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin for cancer therapy and overcoming chemoresistance.
Ranasinghe R; Mathai ML; Zulli A
Heliyon; 2022 Sep; 8(9):e10608. PubMed ID: 36158077
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of cisplatin plus vinorelbine adjuvant chemotherapy with split-dose administration of cisplatin after complete resection of stage II-IIIA non-small cell lung cancer.
Funaguchi N; Iihara H; Kaito D; Gomyo T; Sasaki Y; Yanase K; Endo J; Ito F; Hirose C; Ohno Y; Okura H
Mol Clin Oncol; 2022 Apr; 16(4):76. PubMed ID: 35251627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
